Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Oct
07
Today In Oncology
2026 Albany Prize Awardees Announced
ACS Study Quantifies Financial Burden of Cancer in Older Patients
Refined Risk Index Improves Outcome Prediction After Limited-Duration CLL Therapy
Residual Ovarian Cancer Risk in BRCA Carriers May Inform Timing of Preventive Surgery
The Molecular Watchman Why Measurable Residual Disease Testing Is Redefining Treatment and Surveillance in Colorectal and Bladder Cancers
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo